Science Hub
The Clarida Method
Discover how marine biology, precision formulation, and circadian timing work together as a unified system designed to act on the retinal environment.
Why Marine Biology
The ocean contains some of the most biochemically sophisticated organisms on Earth. Marine microalgae — the foundation of Clarida's formulation — have evolved over hundreds of millions of years to manage oxidative stress, inflammatory signaling, and cellular repair in environments far more demanding than human tissue.
Clarida's ingredients were not selected simply because they are naturally derived. They are selected because they can plausibly influence the specific biological environment where AMD damage occurs — the retinal immune microenvironment, the RPE-Bruch's membrane interface, and the cytokine signaling pathways that determine whether retinal tissue moves toward degeneration or toward a more repair-permissive state.
Spirulina is not treated as a commodity ingredient. Clarida uses strain-specific, clinically characterized Spirulina selected at the genetic and morphological level for compatibility with the cytokine-entrainment protocol. The primary bioactive — C-phycocyanin — is an NF-κB inhibitor with documented anti-inflammatory activity. It is not an antioxidant in the conventional sense. It modulates the upstream inflammatory signaling that drives complement activation, RPE stress, and the chronic immune dysregulation at the heart of AMD pathology.
Chlorella contributes distinct marine carotenoid bioactives absent from any existing AMD supplement. Lutein and zeaxanthin deliver macular carotenoids at the RPE level. Taurine is a major constituent of retinal cells and is associated with membrane integrity. Rutin contributes NLRP3 inflammasome modulation. Together these ingredients form a networked formulation — not a main ingredient with accessories, but a convergent system targeting multiple nodes of retinal inflammatory and oxidative stress simultaneously.
Why Timing Is Part of the Mechanism
Most nutritional supplements operate on a static exposure model. A single daily dose delivers a bolus of nutrients. The body absorbs what it can. The rest is metabolized. There is no attempt to align delivery with the biological windows when those nutrients might be most relevant.
Clarida operates on a different principle. Timing is not incidental to the protocol — it is part of the mechanism.
The retina is a circadian-active tissue. RPE phagocytosis, photoreceptor outer segment shedding, melatonin synthesis, and immune surveillance rhythms are all clock-controlled. The cytokine cascade that enables zebrafish retinal regeneration unfolds in a precise temporal sequence — an early inflammatory signal, a permissive window, a resolution phase. Static once-daily nutrient exposure is not designed to approximate that sequence. Clarida's six-dose protocol is designed around that temporal and circadian logic.
Each of Clarida's six daily doses is delivered at a specific interval aligned with the body's natural repair cycles. The dual-compartment capsule releases ingredients at two distinct pH levels — 6.5 and 7.0 to 7.5 — designed to create separate release phases along the gastrointestinal tract. Nanocarrier-bound pigments improve retinal delivery. The timing model is designed to adjust dose intervals based on individual sleep–wake patterns. It can be further personalized based on OCT findings and cytokine response profiles.
The System View
Clarida's formulation and delivery architecture are not separable. The strain-specific ingredients, the six-dose schedule, the pH-triggered dual-compartment release, and the AI-adjusted personalization layer are interdependent components of a single integrated system. Removing any one of these components changes the proposed biological logic.
This is what distinguishes Clarida from every existing AMD supplement — not a better ingredient list, but a fundamentally different design philosophy. One that treats the retinal microenvironment as a dynamic biological system requiring timed, sequenced, personalized delivery rather than static daily supplementation.
Formal outcomes studies are planned.